RXRX

Business Context and Reporting Period

Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: Recursion is a clinical-stage TechBio company utilizing its Recursion Operating System (OS) to industrialize drug discovery through AI and machine learning. The company focuses on precision oncology and rare diseases. As of September 30, 2024, the company had an accumulated deficit of $1.25 billion and expects to incur substantial operating losses in the future.

Key Financial Metrics

Note: Q3 specific operating cash flow is not provided in the text; only 9-month data is available.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 147% in Q3 2024 compared to Q3 2023, driven primarily by the recognition of a $30.0 million acceptance fee from the Roche-Genentech collaboration for a neuroscience Phenomap. For the nine months ended September 30, 2024, revenue increased 61% year-over-year.
• Expense Increases:
  • R&D Expenses: Increased 7% in Q3 and 26% for the nine months ended September 30, 2024, due to platform expansion, personnel costs, and upgrades to the BioHive supercomputer.
  • G&A Expenses: Increased 29% in Q3 and 26% for the nine months, driven by higher salaries, software costs, and lease expenses.
• Financing Activity: In June 2024, the company completed a public offering of 35.4 million shares, raising net proceeds of approximately $216.4 million. Additionally, $72.9 million was raised via At-The-Market (ATM) offerings during the nine-month period.
• Acquisitions: The company signed an agreement on August 8, 2024, to acquire Exscientia plc in an all-stock transaction. The deal is subject to shareholder and regulatory approvals.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash and cash equivalents ($427.6 million) are sufficient to fund operations for at least the next 12 months. However, the company expects to require additional capital to advance drug candidates and commercialize products.
• Pipeline Highlights:
  • REC-994 (CCM): Phase 2 SYCAMORE trial met primary safety endpoint with encouraging efficacy trends.
  • REC-2282 (NF2): Phase 2/3 POPLAR trial enrollment for adults is complete; update expected in Q4 2024.
  • REC-3964 (C. diff): First patient dosed in Phase 2 ALDER trial in October 2024.
  • REC-1245 (RBM39): IND cleared by FDA; Phase 1/2 dosing expected to initiate in Q4 2024.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to revenue recognition cost models. While remediation steps have been taken, management concluded the weakness was not fully remediated as of September 30, 2024.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing, potential dilution from future equity issuances, and the successful integration of the proposed Exscientia acquisition.

Investor Verification Checklist

• Exscientia Acquisition Status: Verify the progress of shareholder and regulatory approvals for the proposed acquisition of Exscientia plc.
• Roche Collaboration Milestones: Confirm the timing and probability of future milestone payments and option exercises under the Roche-Genentech agreement.
• Internal Control Remediation: Monitor future filings for confirmation that the material weakness in revenue recognition controls has been fully remediated.
• Cash Burn Rate: Assess the sustainability of the current cash position ($427.6 million) against the projected operating losses and capital expenditure requirements for the next 12-24 months.
• Clinical Trial Readouts: Track upcoming data releases for REC-994, REC-2282, and REC-1245 to validate the company's pipeline value proposition.